[go: up one dir, main page]

WO2025178968A3 - Variants fonctionnels non codants utilisés en tant que biomarqueurs du cancer - Google Patents

Variants fonctionnels non codants utilisés en tant que biomarqueurs du cancer

Info

Publication number
WO2025178968A3
WO2025178968A3 PCT/US2025/016495 US2025016495W WO2025178968A3 WO 2025178968 A3 WO2025178968 A3 WO 2025178968A3 US 2025016495 W US2025016495 W US 2025016495W WO 2025178968 A3 WO2025178968 A3 WO 2025178968A3
Authority
WO
WIPO (PCT)
Prior art keywords
variants
coding
maputr
cancer
function
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/US2025/016495
Other languages
English (en)
Other versions
WO2025178968A2 (fr
Inventor
Xinshu XIAO
Ting Fu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California Berkeley
University of California San Diego UCSD
Original Assignee
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California Berkeley, University of California San Diego UCSD filed Critical University of California Berkeley
Publication of WO2025178968A2 publication Critical patent/WO2025178968A2/fr
Publication of WO2025178968A3 publication Critical patent/WO2025178968A3/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La compréhension de la fonction de variants non codants rares représente un défi majeur. Au moyen de MapUTR, un procédé de criblage, nous avons étudié la fonction de variants de 3'-UTR rares affectant l'abondance d'ARNm de manière post-transcriptionnelle. Des variants de MapUTR fonctionnels ont été enrichis en sites de liaison au microARN ou à la protéine et peuvent être sous-jacents à l'expression génique aberrante dans des tumeurs. En outre, nous présentons une charge mutationnelle tumorale non traduite (uTMB), une métrique reflétant la quantité de variants MapUTR fonctionnels somatiques d'une tumeur et démontrons son potentiel dans la prédiction de la survie du patient. Par l'édition primaire, nous avons caractérisé trois variants dans des gènes pertinents pour le cancer (MFN2, FOSL2 et IRAK1), démontrant leur potentiel d'induction du cancer. La présente divulgation élucide la fonction de dizaines de milliers de variants non codants, désigne des mutations non codantes du conducteur du cancer et décrit des méthodes pour leur utilisation dans la gestion de cancers.
PCT/US2025/016495 2024-02-21 2025-02-19 Variants fonctionnels non codants utilisés en tant que biomarqueurs du cancer Pending WO2025178968A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202463556202P 2024-02-21 2024-02-21
US63/556,202 2024-02-21

Publications (2)

Publication Number Publication Date
WO2025178968A2 WO2025178968A2 (fr) 2025-08-28
WO2025178968A3 true WO2025178968A3 (fr) 2025-09-25

Family

ID=96847928

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2025/016495 Pending WO2025178968A2 (fr) 2024-02-21 2025-02-19 Variants fonctionnels non codants utilisés en tant que biomarqueurs du cancer

Country Status (1)

Country Link
WO (1) WO2025178968A2 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050143334A1 (en) * 2002-12-20 2005-06-30 David Tarin Genetic markers and methods for the diagnosis, treatment and prevention of tumor metastasis
WO2016018481A2 (fr) * 2014-07-28 2016-02-04 The Regents Of The University Of California Stratification de mutations tumorales basée sur des réseaux

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050143334A1 (en) * 2002-12-20 2005-06-30 David Tarin Genetic markers and methods for the diagnosis, treatment and prevention of tumor metastasis
WO2016018481A2 (fr) * 2014-07-28 2016-02-04 The Regents Of The University Of California Stratification de mutations tumorales basée sur des réseaux

Also Published As

Publication number Publication date
WO2025178968A2 (fr) 2025-08-28

Similar Documents

Publication Publication Date Title
Grimm et al. High dose per fraction, hypofractionated treatment effects in the clinic (HyTEC): an overview
Burdach et al. High-dose chemoradiotherapy (HDC) in the Ewing family of tumors (EFT)
Bae et al. The prognoses of metaplastic breast cancer patients compared to those of triple-negative breast cancer patients
Langendijk et al. Postoperative radiotherapy in squamous cell carcinoma of the oral cavity: the importance of the overall treatment time
Nahum The radiobiology of hypofractionation
Moreno et al. At the frontier of progress for paediatric oncology: the neuroblastoma paradigm
Cascinu et al. Colorectal cancer in the adjuvant setting: perspectives on treatment and the role of prognostic factors
Langendijk et al. The importance of pre-treatment haemoglobin level in inoperablenon-small cell lung carcinoma treated with radical radiotherapy
Harting et al. Single-cell-based computer simulation of the oxygen-dependent tumour response to irradiation
Blucher et al. Precision oncology for breast cancer through clinical trials
WO2025178968A3 (fr) Variants fonctionnels non codants utilisés en tant que biomarqueurs du cancer
Badiu et al. Balancing robustness and adaptation rate for proton therapy of lung cancer patients
Noguchi et al. Establishment and characterization of NCC-MFS2-C1: a novel patient-derived cancer cell line of myxofibrosarcoma
Tessone et al. Radiotherapy-induced basal cell carcinomas of the scalp: are they genetically different?
Cabrera-Rodríguez The role of radiotherapy in the treatment of oral cavity cancer
Altundag et al. Addition of granulocyte-colony stimulating factor (G-CSF) to adjuvant treatment may increase survival in patients with operable breast cancer: interaction of G-CSF with dormant micrometastatic breast cancer cells
Velez-Velez et al. Clinical value of pharmacogenomic testing in a patient receiving FOLFIRINOX for pancreatic adenocarcinoma
Ruiz et al. Chronological occurrence of PI3KCA mutations in breast cancer liver metastases after repeat partial liver resection
Daugaard et al. Primary radiotherapy of carcinoma of the supraglottic larynx—A multivariate analysis of prognostic factors
Tarlock et al. Mesothelin expression is associated with extramedullary disease and promotes in vivo leukemic growth in acute myeloid leukemia
Wang et al. 179P Neoadjuvant camrelizumab plus nab-paclitaxel and epirubicin for early triple-negative breast cancer: A single-arm, open-label, phase II study
Lubas et al. Proton therapy in the palliative setting
Kapiris et al. A retrospective analysis of 66 colorectal cancer cases from Guy’s and St Thomas’(GSTT) Molecular Tumour Board
Pezzolo et al. Germ line polymorphisms as predictive markers for pre-surgical radiochemotherapy in locally advanced rectal cancer: a 5-year literature update and critical review
Xiao-bo Research progress of surgical approach for laparoscopic pancreatoduodenectomy